Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HDDO-1756 FDC vs Loose Combination in Healthy Volunteers
NCT04755894Phase 1Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ezetimibe and fenofibrate in hyperlipidemia (2 arms), sponsored by Hyundai Pharmaceutical Co., Ltd. Primary endpoint: pharmacokinetic evaluation variables. Started Jun 2020; status: completed.
02
Drugs
ezetimibefenofibrate
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT04755894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755894.